BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 9029057)

  • 1. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
    Fitzsimmons ME; Collins JM
    Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
    Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
    Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
    Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
    Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
    Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
    Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
    J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
    Chiba M; Hensleigh M; Lin JH
    Biochem Pharmacol; 1997 Apr; 53(8):1187-95. PubMed ID: 9175724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
    Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
    Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
    Rodrigues AD; Mulford DJ; Lee RD; Surber BW; Kukulka MJ; Ferrero JL; Thomas SB; Shet MS; Estabrook RW
    Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA; Profit L; Back DJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
    Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
    Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
    Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
    Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
    Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
    Gallagher EP; Wienkers LC; Stapleton PL; Kunze KL; Eaton DL
    Cancer Res; 1994 Jan; 54(1):101-8. PubMed ID: 8261428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.
    Oda Y; Kharasch ED
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1021-32. PubMed ID: 11504799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
    Emoto C; Yamazaki H; Iketaki H; Yamasaki S; Satoh T; Shimizu R; Suzuki S; Shimada N; Nakajima M; Yokoi T
    Xenobiotica; 2001 May; 31(5):265-75. PubMed ID: 11491388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
    Raeissi SD; Guo Z; Dobson GL; Artursson P; Hidalgo IJ
    Pharm Res; 1997 Aug; 14(8):1019-25. PubMed ID: 9279883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.